SUVENBSESuven Life Sciences Ltd· Healthcare ServicesHighNeutral
Announced Wed, 8 Jul, 2026 · 12:51 IST

Suven allots 1.85 cr shares on warrant conversion; sets up Singapore WOS

Warrants ConvertedFund Raising View source PDFExplain this filing

SUVEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+0.2%Reaction day
₹317.50
prior close
₹321.75
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-2.0%+2.2% vs market
Healthcare Research Analytics & Technology peers, median of 5sector+0.0%+0.2% vs sector

On the reaction day the stock moved 2.2 pts more than Nifty Microcap 250 and 0.2 pts more than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.1
10m
+0.1
15m
+0.9
30m
+0.8
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+0.2-2.0+2.2+0.0+0.2
Next day
+10.2-0.1+10.4+1.0+9.2
2d
+12.3+1.2+11.0+2.6+9.7
3d
+13.1+1.4+11.7+0.5+12.6
4d
+9.9+0.4+9.6-0.1+10.0
5d
+12.5+1.0+11.5+1.6+10.9
1w
+2.2-0.5+2.7-1.1+3.3
15d
-1.5-0.6-0.9-2.0+0.6
1m
+5.2+3.4+1.8-2.0+7.2
2m
+16.5+6.0+10.5+13.4+3.1
3m
-9.5+1.1-10.6+0.2-9.7
UpDownMarket · Nifty Microcap 250Sector · Healthcare Research Analytics & Technology peers, median of 5Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved conversion of 1,85,70,133 warrants into equity shares at Rs 134 each to 17 non-promoter allottees, raising about Rs 248.84 crore. Paid-up equity capital rose to 28.26 crore shares. Also re-appointed Dr. Vajja Sambasiva Rao as Independent Director for 5 years from Jan 2027. Incorporated wholly owned subsidiary Suven Neurosciences Pte. Ltd. in Singapore with planned investment of USD 100 million for neurological therapeutics.

Likely market impact

Dilution from warrant conversion already priced in. Fresh capital strengthens balance sheet; Singapore WOS signals overseas push into neuro therapeutics.